within Pharmacolibrary.Drugs.D_Dermatologicals.D01A_AntifungalsForTopicalUse.D01AE15_Terbinafine;

model Terbinafine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.45,
    Cl = 4.388888888888889e-06,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 0.9,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01155,
    Tlag = 3600,
    Vdp = 0.73,
    k12 = 1.9055555555555555e-05,
    k21 = 1.9055555555555555e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Terbinafine</td></tr><tr><td>ATC code:</td><td>D01AE15</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>900</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Terbinafine is an allylamine antifungal agent primarily used for the treatment of dermatophyte infections such as onychomycosis (fungal nail infections) and tinea infections of the skin. It acts by inhibiting squalene epoxidase, a key enzyme in fungal ergosterol synthesis. Terbinafine is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), following single and multiple oral doses.</p><h4>References</h4><ol><li><p>Scher, RK (1999). Onychomycosis: therapeutic update. <i>Journal of the American Academy of Dermatology</i> 40(6 Pt 2) S21–S26. DOI:<a href=\"https://doi.org/10.1016/s0190-9622(99)70397-x\">10.1016/s0190-9622(99)70397-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10367912/\">https://pubmed.ncbi.nlm.nih.gov/10367912</a></p></li><li><p>Gupta, AK, et al., &amp; Cooper, EA (2003). The efficacy and safety of terbinafine in children. <i>Journal of the European Academy of Dermatology and Venereology : JEADV</i> 17(6) 627–640. DOI:<a href=\"https://doi.org/10.1046/j.1468-3083.2003.00691.x\">10.1046/j.1468-3083.2003.00691.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14761128/\">https://pubmed.ncbi.nlm.nih.gov/14761128</a></p></li><li><p>Gupta, AK, et al., &amp; Cooper, EA (2024). Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis. <i>Expert opinion on pharmacotherapy</i> 25(15) 1983–1998. DOI:<a href=\"https://doi.org/10.1080/14656566.2024.2416924\">10.1080/14656566.2024.2416924</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39394930/\">https://pubmed.ncbi.nlm.nih.gov/39394930</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D01AE15 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Terbinafine;
